Development
Cullinan Therapeutics, Inc.
CGEM
$7.85
-$0.235-2.91%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -237.72% | -248.03% | -225.52% | 184.22% | 269.61% |
| Total Depreciation and Amortization | 233.33% | 534.78% | 342.00% | 198.04% | 75.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 107.59% | 109.57% | 109.63% | -3,154.89% | -1,072.28% |
| Change in Net Operating Assets | -103.03% | -139.47% | -173.47% | 51.11% | 415.62% |
| Cash from Operations | -6.01% | -20.77% | -120.86% | -144.03% | -191.63% |
| Capital Expenditure | 81.64% | -334.26% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -100.00% | -98.15% | -- | -- |
| Other Investing Activities | 244.15% | -232.22% | -361.51% | 72.51% | 92.52% |
| Cash from Investing | -85.62% | -116.92% | -120.16% | 242.22% | 174.59% |
| Total Debt Issued | -23.16% | -9.09% | -9.09% | 325.00% | -- |
| Total Debt Repaid | -- | 100.00% | 100.00% | -- | -- |
| Issuance of Common Stock | 546.61% | 355.82% | 423.11% | -8.98% | -97.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -2,986.47% | -2,986.47% | -1,704.87% | -1,720.28% |
| Cash from Financing | 257.14% | -21.59% | 0.78% | -457.46% | -109.65% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -159.89% | -215.05% | -192.10% | 121.16% | 188.89% |